Cerebrolysin: a multi-target drug for recovery after stroke
Summary
Expert review synthesizing clinical evidence for Cerebrolysin in stroke recovery. Found that effect size increases with stroke severity, with significant benefits in moderate to severe ischemic stroke patients. Can be safely combined with thrombolysis and enhances functional recovery when combined with neurorehabilitation.
Key Findings
- Effect size of Cerebrolysin increases with stroke severity — most effective in moderate to severe cases
- Safe combination with thrombolysis demonstrated in controlled studies
- Significant functional recovery benefit when combined with neurorehabilitation versus rehabilitation alone
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Related Studies
View all →Cerebrolysin reduces astrogliosis and axonal injury and enhances neurogenesis in rats after closed head injury
Zhang Y, Chopp M, Zhang ZG, et al.
Neurorehabilitation and Neural Repair
Prospective, randomized, blinded, placebo-controlled study showing Cerebrolysin significantly improved cognitive and sensorimotor function after mild traumatic brain injury in rats. Treatment reduced astrogliosis and axonal damage while promoting neurogenesis in the dentate gyrus, with dose-dependent effects.
- Cerebrolysin reduced amyloid precursor protein accumulation and astrogliosis after TBI
- Dose-dependent improvement in cognitive and sensorimotor function sustained at 90 days
The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders
Masliah E, Díez-Tejedor E
Drugs of Today
Comprehensive pharmacological review demonstrating that Cerebrolysin mimics endogenous neurotrophic factors. In dementia models, it decreased amyloid-beta deposition and tau phosphorylation, increased synaptic density, and enhanced neurogenesis. In stroke models, it reduced infarct volume and promoted functional recovery.
- Decreased amyloid-beta deposition and tau phosphorylation via GSK-3beta and CDK5 regulation
- Enhanced neurogenesis in the dentate gyrus and subventricular zone